Coya Therapeutics Inc. has announced results from a preclinical in vivo animal study evaluating its investigational biologic combination, COYA 303, which consists of low-dose IL-2 and a GLP-1 receptor agonist. The study used a lipopolysaccharide (LPS) mouse model to simulate systemic and neurological inflammation representative of chronic conditions such as neurodegenerative diseases. According to the company's announcement, COYA 303 treatment significantly reduced peripheral pro-inflammatory cell expansion, enhanced regulatory T cell function, attenuated central nervous system inflammation, and promoted a shift of macrophages to an anti-inflammatory phenotype compared to controls. These findings confirm interim results previously reported by the company. Coya Therapeutics intends to publish the full dataset in the future.